Heart Failure study: Vericiguat
Official title COgnitioN With VERiciGuat Evaluation in Heart Failure
ClinicalTrials.gov ID: NCT06601465
What this study is testing
What is Vericiguat?
An investigational oral tablet being studied as a potential treatment for heart failure in patients with mild-to-moderate cognitive impairment. It is designed to stimulate soluble guanylate cyclase (sGC) and increase cyclic GMP levels in the body.
Also referred to as Verquvo.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if vericiguat can improve heart‑failure symptoms and cognitive function in these patients.
- Who it's for
- Adults who have chronic heart failure for at least six months and mild‑to‑moderate cognitive impairment.
- What's involved
- Participants will be randomly assigned to receive vericiguat or a control treatment and will attend scheduled clinic visits and undergo tests to monitor heart‑failure and cognitive status.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult patients
- Established chronic heart failure (≥ 6 months)
- Mild-to-moderate cognitive impairment (as per the diagnosis of cognitive impairment or a Montreal Cognitive Assessment (MoCA) score 10-25).
You likely can't join if
- Patients who have contraindications for sGC stimulator and vericiguat therapy (i.e.
- Unable to undergo CMR imaging or brain MRI.
- CMR exclusions: incompatible implantable cardiac device (ICD or CRT), uncontrolled atrial fibrillation or recurrent ventricular arrhythmias).
- General medical conditions: uncontrolled thyroid disorders, hepatic failure, or myocardial revascularization procedures [coronary angioplasty and/or...
- Patients with allergies to the study products.
- Patients currently hospitalized.
The study team makes the final eligibility decision.
Where it is enrolling
- Calgary, Alberta, Canada
- Edmonton, Alberta, Canada
- Ottawa, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Calgary, Alberta, Canada; Edmonton, Alberta, Canada; Ottawa, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.